Overview

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Status:
Recruiting

Trial end date:
2023-01-31

Target enrollment:

Participant gender:

Summary

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 52 weeks by subjects with atopic dermatitis (eczema).

Phase:

Phase 3

Details

Lead Sponsor:

Arcutis Biotherapeutics, Inc.